New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT(®) cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. The analysis showed that highly adherent participants who remained on icosapent ethyl (IPE) treatment for at least 1.5 years experienced approximately 30% relative risk reduction in major adverse cardiovascular events. Additionally, secondary prevention participants who stopped IPE treatment prematurely after a mean of 2.3 years exhibited a “legacy” effect with no apparent diminution in the hazard ratio (HR) difference over the next one to four years.

"REDUCE-IT remains a landmark cardiovascular outcomes trial in preventive cardiology, and more than seven years after its completion we continue to generate meaningful insights from this important dataset," said Steven Ketchum, Ph.D., EVP, President R&D, & Chief Scientific Officer at Amarin. "The findings from this analysis suggest that patients who remained adherent on treatment long enough to achieve the full benefit of therapy may continue to experience cardiovascular protection for additional years after discontinuation. While exploratory in nature, these data provide important insights into the durability of the treatment effect and add to the body of scientific evidence generated from REDUCE-IT."